Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ - mediated psoriasis-like skin disease in vivo

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Hack, Katrin ^a   Reilly, Louise ^a   Palmer, Colin ^a   Read, Kevin D ^a   Norval, Suzanne ^a   Kime, Robert ^a   Booth, Kally ^b   Foerster, John ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Medical School Biological Resource Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; GSK 0660; GSK 3787; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA ANTAGONIST; UNCLASSIFIED DRUG; 3 [(4 ANILINO 2 METHOXYPHENYL)SULFAMOYL] 2 THENOIC ACID METHYL ESTER; 4 CHLORO N (2 ((5 TRIFLUOROMETHYL 2 PYRIDYL)SULFONYL)ETHYL)BENZAMIDE; 4-CHLORO-N-(2-((5-TRIFLUOROMETHYL-2-PYRIDYL)SULFONYL)ETHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECOMBINANT PROTEIN; SULFONE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; MOUSE; NONHUMAN; PSORIASIS; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; OINTMENT; PATHOLOGY; SKIN; SKIN ABSORPTION; TOPICAL DRUG ADMINISTRATION; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ADMINISTRATION, TOPICAL; ANIMALS; BENZAMIDES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OINTMENTS; PPAR GAMMA; PPAR-BETA; PSORIASIS; RECOMBINANT PROTEINS; SKIN; SKIN ABSORPTION; SULFONES; THIOPHENES;

EID: 84860994978     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037097     Document Type: Article

References (33)

1. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M, (2006) Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298: 321-328.
2. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, et al. (2005) Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125: 61-67.
3. de Lange P, Lombardi A, Silvestri E, Goglia F, Lanni A, et al. (2008) Peroxisome Proliferator-Activated Receptor Delta: A Conserved Director of Lipid Homeostasis through Regulation of the Oxidative Capacity of Muscle. PPAR Res 2008 172676.
4. Romanowska M, Reilly L, Palmer CN, Gustafsson MC, Foerster J, (2010) Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS One 5: e9701.
5. Icre G, Wahli W, Michalik L, (2006) Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis. J Investig Dermatol Symp Proc 11: 30-35.
6. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, et al. (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15: 3263-3277.
7. Di-Poi N, Michalik L, Tan NS, Desvergne B, Wahli W, (2003) The anti-apoptotic role of PPARbeta contributes to efficient skin wound healing. J Steroid Biochem Mol Biol 85: 257-265.
8. Icre G, Wahli W, Michalik L, (2006) Functions of the Peroxisome Proliferator-Activated Receptor (PPAR) alpha and beta in Skin Homeostasis, Epithelial Repair, and Morphogenesis. J Invest Dermatol 126 Suppl pp. 30-35.
9. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, et al. (2006) Activation of PPAR{beta}/{delta} Induces Endothelial Cell Proliferation and Angiogenesis. Arterioscler Thromb Vasc Biol.
10. Azfar RS, Gelfand JM, (2008) Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 20: 416-422.
11. Sun L, Ke Y, Zhu CY, Tang N, Tian DK, et al. (2008) Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats. Chin Med J (Engl) 121: 2305-2311.
12. Masternak MM, Al-Regaiey KA, Del Rosario Lim MM, Bonkowski MS, Panici JA, et al. (2005) Caloric restriction results in decreased expression of peroxisome proliferator-activated receptor superfamily in muscle of normal and long-lived growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 60: 1238-1245.
13. Kasuga J, Ishida S, Yamasaki D, Makishima M, Doi T, et al. (2009) Novel biphenylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) delta selective antagonists. Bioorg Med Chem Lett 19: 6595-6599.
14. Zaveri NT, Sato BG, Jiang F, Calaoagan J, Laderoute KR, et al. (2009) A novel peroxisome proliferator-activated receptor delta antagonist, SR13904, has anti-proliferative activity in human cancer cells. Cancer Biol Ther 8: 1252-1261.
15. Shearer BG, Wiethe RW, Ashe A, Billin AN, Way JM, et al. (2010) Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. J Med Chem 53: 1857-1861.
16. Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, et al. (2010) Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol 78: 419-430.
17. Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, et al. (2008) Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist. Mol Endocrinol 22: 523-529.
18. Hall JM, McDonnell DP, (2007) The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. Mol Endocrinol 21: 1756-1768.
19. Kobayashi N, Saitoh I, (1998) A method to measure the solubility of drugs in ointment bases. Chem Pharm Bull (Tokyo) 46: 1833-1835.
20. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, et al. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98: 5306-5311.
21. Romanowska M, Reilly L, Palmer CN, Gustafsson MC, Foerster J, (2010) Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS One 5: e9701.
22. Romanowska M, al Yacoub N, Seidel H, Donandt S, Gerken H, et al. (2008) PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128: 110-124.
23. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, et al. (2006) Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 25: 1225-1241.
24. Wang LH, Yang XY, Zhang X, Huang J, Hou J, et al. (2004) Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Immunity 20: 205-218.
25. Malhotra S, Bansal D, Shafiq N, Pandhi P, Kumar B, (2005) Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis. Expert Opin Pharmacother 6: 1455-1461.
26. Kuenzli S, Saurat JH, (2003) Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study. Dermatology 206: 252-256.
27. Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U, (2005) Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 44: 126-129.
28. Woollard PM, (1986) Stereochemical difference between 12-hydroxy-5,8,10,14-eicosatetraenoic acid in platelets and psoriatic lesions. Biochem Biophys Res Commun 136: 169-176.
29. Romanowska M, Al Yacoub N, Seidel H, Donandt S, Gerken H, et al. (2007) PPARdelta Enhances Keratinocyte Proliferation in Psoriasis and Induces Heparin-Binding EGF-Like Growth Factor. J Invest Dermatol.
30. Barish GD, Atkins AR, Downes M, Olson P, Chong LW, et al. (2008) PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci U S A 105: 4271-4276.
31. Pollock CB, Rodriguez O, Martin PL, Albanese C, Li X, et al. (2010) Induction of metastatic gastric cancer by peroxisome proliferator-activated receptordelta activation. PPAR Res 2010 571783.
32. Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E, (2010) Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 6: 704-714.
33. Sterry W, Foerster J, (2005) What must a model display for proof as a model of psoriasis? In Ernst Schering Res Found Workshop pp. 193-201.